AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Personalis, Inc. to Present at Precision Medicine World Conference 2020

January 22, 2020 GMT

MENLO PARK, Calif.--(BUSINESS WIRE)--Jan 22, 2020--

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Precision Medicine World Conference (PMWC) 2020 in Santa Clara, CA January 22-24.

The presentation titled “Enabling Advanced Composite Biomarkers for Precision Oncology and Cancer Diagnostics,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT ™. Richard Chen, MS, MD, Chief Scientific Officer, will present for Personalis. Dr. Chen will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics, including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.

ImmunoID NeXT ™ is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a single tumor specimen.

Personalis will also be exhibiting during the conference (Exhibit #D2820). Representatives will be available to answer questions about the company’s cancer immunogenomics capabilities.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).

View source version on businesswire.com:https://www.businesswire.com/news/home/20200122005605/en/

CONTACT: Investor Relations Contact for Personalis:

Caroline Corner

investors@personalis.com

www.westwicke.com

415-202-5678Media Contact for Personalis:

Jennifer Havlek

pr@personalis.com

www.personalis.com

650-752-1300

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH GENETICS CLINICAL TRIALS

SOURCE: Personalis, Inc.

Copyright Business Wire 2020.

PUB: 01/22/2020 12:15 PM/DISC: 01/22/2020 12:15 PM

http://www.businesswire.com/news/home/20200122005605/en